Mangoceuticals Inc. is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc. is based in DALLAS, TX.
| Revenue (Most Recent Fiscal Year) | $0.62M |
| Net Income (Most Recent Fiscal Year) | $-8.71M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 24.53 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2191.76% |
| Net Margin (Trailing 12 Months) | -2191.76% |
| Return on Equity (Trailing 12 Months) | -72.81% |
| Return on Assets (Trailing 12 Months) | -66.58% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 31.81 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.92 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Common Shares Outstanding | 5.17M |
| Free Float | 4.34M |
| Market Capitalization | $12.51M |
| Average Volume (Last 20 Days) | 0.18M |
| Beta (Past 60 Months) | 2.45 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 56.72% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |